Evolution of intravesical immunotherapy for bladder cancer:

**Curis helping to treat cancer, neurological degenerative, kidney disorders, CUDC-101. Pathways, hedgehog, EGFR, Her2, Hsp90, Bcr-Abl/Src, CDK, BCL, MEK, VEGF, HDAC.**

Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Expert Opinion's
Reply to topic
Evolution of intravesical immunotherapy for bladder cancer:
RSS FEED


Joined: 05 Apr 2006
Posts: 19275
Post Posted: Mon Jun 23, 2008 1:31 pm Reply with quote


Expert Opinion on Investigational Drugs , July 2008, Vol. 17, No. 7, Pages 1067-1073.
<br/>
Background: The intra-cavitary administration of antineoplastic agents for the treatment of non-invasive bladder cancer has met with variable results. Mytomicin-C (MCC) is effective in the prevention of tumor recurrence when administered in the immediate ...

Read more...

Source: Expert Opinion: Expert Opinion on Investigational Drugs: Table of Contents
Table of Contents for Expert Opinion on Investigational Drugs. List of articles from both the latest and ahead of print issues.
View user's profileSend private message
Evolution of intravesical immunotherapy for bladder cancer:
All times are GMT - 7 Hours  
Page 1 of 1  
  
  
Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Expert Opinion's
 Reply to topic  
Forum Map
Site Map